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Abstract 
Neuroblastoma is the most common extracranial solid tumour in childhood and nearly half of 
neuroblastoma cases occur in children less than two years of age. This cancer is thought to 
arise due to an alteration during neuronal differentiation and only 30 % of patients with high-
risk tumours survive. High-risk neuroblastoma cases are treated with retinoic acid to induce 
differentiation of the tumour cells left after tumour resection, but these tumours are usually 
refractive to retinoic acid and other post-surgery therapies. Intriguingly, a positive outcome 
for low risk disease correlates with high expression levels in the tumour of a neuronal isoform 
of the ubiquitously expressed C-Src kinase, N2-Src kinase, which is thought to induce 
spontaneous differentiation of the neuroblastoma to a harmless neuronal 
phenotype.  Indeed, preliminary experiments in our laboratory have shown that 
overexpression of N2-Src in retinoic acid-resistant neuroblastoma cells is sufficient to 
differentiate them. It was also shown that N2-Src kinase interacts with proteins of the COPII 
complex, which coats secretory vesicles that traffic from the ER to the Golgi apparatus, and, 
interestingly, a preliminary finding showed that the overexpression of the COPII protein 
Sec23A disrupts N2-Src-dependent differentiation. 
In this study, I investigated the interplay between N2-Src and the COPII complex in an 
inducible N2-Src expressing cell line. The aims of my research were to i) understand how N2-
Src regulates COPII transport and to ii) design and validate a tool that can be used to 
understand whether the N2-Src dependent effects on cell morphology and migration require 
the COPII complex. I observed the trend of N2-Src decreasing migration, both in a random 
migration assay and in a wound healing assay. Moreover, an assay for COPII transport 
revealed a trend of N2-Src increasing the number of secretory vesicles. Furthermore, these 
vesicles were eventually redistributed along neurite-like processes that the cells extend when 
they express the kinase. I also designed and validated some shRNA constructs able to silence 
the protein expression of the COPII coat protein Sec23A, which could be used to verify if the 
silencing of this protein increases N2-Src-dependent differentiation. 
Taken together, these data lead to the conclusion that N2-Src might regulate COPII 
transport. Future differentiation therapies for neuroblastoma could be targeted to the N2-
Src/COPII pathway. 
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1. Introduction 
1.1. An overview of neural development 
Mammalian neural development is one of the earliest processes to begin and the last to be 
completed after birth. This process generates the most complex structure within the embryo 
and the long period of development means in utero insult during pregnancy may have 
consequences for the development of the nervous system. 
Neurulation is the folding process in vertebrate embryos through which the neural 
plate is transformed into the neural tube (Larsen 2001). After the formation of the neural 
plate (Fig. 1A), the edges of this structure thicken and move upward to form the neural fold. 
This generates the neural groove, which starts to divide the future right and left sides of the 
embryo (Fig. 1B). Eventually, the migrating neural fold fuses to form the neural tube beneath 
the overlaying ectoderm and the cells at the most dorsal portion of this structure become the 
neural crest cells (Fig. 1C) (Darnell and Gilbert 2017, Nikolopoulou et al. 2017). 
Figure 1. Overview of neurulation. Schematic representation of neurulation, which involves the 
elevation of the neural folds from the neural plate (A), their bedding to form the neural groove (B) and 
eventually fusion to form the neural tube (C) (adapted from Binz (2016)). 
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The neural crest structure can be divided into four domains that will generate different 
cell types (Bronner and LeDouarin 2012): the cephalic neural portion, which will produce the 
craniofacial mesenchyme that differentiate into the skeletal and connective tissue 
components of the head; the trunk neural crest, whose cells will become melanocytes and 
sensory neurons of the dorsal root ganglia; the vagal and sacral portion, which will generate 
the enteric ganglia of the gut; the cardiac neural crest, which can develop into melanocytes, 
neurons, cartilage, and connective tissue, but will also produce the musculo-connective tissue 
wall of the large arteries, as well as the septum that separates the pulmonary circulation from 
the aorta (Le Lièvre and Le Douarin 1975). 
The neuroblast progenitors that will generate the sympathetic ganglia originate from 
neural crest progenitors in the trunk region of the embryo and follow a ventral migratory 
pathway from the neural crest and around the neural tube, to a region that is lateral to the 
notochord and dorsal aorta (Marshall et al. 2014). In this area, they receive signals from the 
somites, the ventral part of the neural tube, the notochord and the dorsal aorta (Huber 2006).  
An important transcription factor that is normally expressed during the 
sympathoadrenal development is the MYCN proto-oncogene. MYCN belongs to the MYC 
proto-oncogene family, which includes two other paralogous proto-oncogenes (c-MYC and 
MYCL) that are all located on different chromosomes and expressed at specific times during 
development (Mathsyaraja and Eisenman 2016, Wilde and Ayer 2015). MYCN is situated on 
the human chromosome 2p24.3 (Schwab et al. 1984) and is a transcription factor that belongs 
to a class of proteins that contain a basic-region/helix-loop-helix/leucine-zipper (bHLHZip), 
important for protein dimerization and sequence-specific DNA binding (Gherardi et al. 2013). 
This proto-oncogene is important in regulating processes such as cell growth, differentiation 
and apoptosis, but aberrant regulation of MYCN is often observed in cancers and can lead to 
dysregulated cell proliferation (Wilde and Ayer 2015). 
During normal sympathoadrenal development, MYCN expression is high in the post 
migratory neural crest cells because it regulates the migration and expansion of the neural 
crest cells (Zimmerman et al. 1986). Its levels are subsequently reduced when the cells are 
differentiating into sympathetic neurons. While the excess neural precursors undergo 
apoptotic cell death, a process promoted by neural growth factor (NGF) deprivation (Yuan 
and Yankner 2000), the bone morphogenetic protein (BMP) signalling derived from the dorsal 
aorta promotes the specification of the neuronal and catecholaminergic properties of the 
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primary sympathetic ganglia (Huber 2006, Reissmann et al. 1996, Schneider et al. 1999). It is 
believed that the aberrant differentiation of neural crest cells during development causes the 
tumour pathology associated with childhood neuroblastoma (Marshall et al. 2014). 
1.2. Neuroblastoma 
The onset of cancer is a multi-step process that induces genomic instability and life-
threatening cellular phenotypes. However, the evidence that a minority of cancer cells 
possess embryonal features or the plasticity to revert to embryonal features during postnatal 
life has led to the cancer stem cell hypothesis (Valent et al. 2012), which describes the 
heterogeneity that is evident in tumours. 
In some childhood cancers such as neuroblastoma, the precursor hyperplasia of 
embryonal cells has a tendency to undergo spontaneous regression and cell death (Nuchtern 
et al. 2012). It is known that during embryogenesis many more cells are produced than are 
required for organogenesis but mechanisms such as trophic factor withdrawal remove cells 
that are in excess after organogenesis is complete. Unfortunately, in some cases embryonal 
cells can resist cell death signals, and later acquire additional alterations, which can lead to 
postnatal malignant transformation (Marshall et al. 2014). 
Neuroblastoma is the most common extracranial solid tumour in childhood and nearly 
half of neuroblastoma cases occur in children less than two years of age (Stafman and Beierle 
2016). Neuroblastoma arises from the sympathoadrenal lineage of the neural crest, and 
therefore tumours can develop anywhere in the sympathetic nervous system (Maris et al. 
2007). There have been several staging systems for neuroblastoma, but currently the most 
widely used is the International Neuroblastoma Staging System (INSS), which combines 
clinical and surgical staging (Brodeur et al. 1993, Goldsby and Matthay 2004, Matthay et al. 
2016). This system comprises 5 different stages of neuroblastoma, relating to risk: the low-
risk group is composed of patients with Stage 1, 2A and 2B neuroblastoma, who all have 
localized tumours with or without complete gross excision; the intermediate group comprises 
Stage 3 patients, who have an unresectable unilateral tumour; and finally the high-risk group, 
which includes Stage 3 patients with an unresectable tumour and MYCN amplification, and 
Stage 4 patients, who have a primary tumour with dissemination to distant lymph nodes, 
bone marrow, liver and other organs (Brodeur et al. 1993). The INSS also identifies Stage 4S, 
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which represents a specific subset of patients younger than 1 year old, with tumours that tend 
to spontaneously remit (Goldsby and Matthay 2004). 
Many clinical and experimental features link neuroblastoma to altered embryogenesis 
(Marshall et al. 2014). A significant percentage of stage 4S patients with neuroblastoma in 
early childhood have spontaneous regression without therapy. Moreover, the autopsies of 
sympathoadrenal tissues from children whose cause of death was not cancer show an 
incidence of neuroblast pre-cancer cells that is higher than the incidence of clinical 
neuroblastoma (Beckwith and Perrin 1963). Patients’ biopsies show that the tumour cells are 
arrested at various stages of neuronal differentiation and the grade of differentiation 
correlates with clinical course (Wilson and Draper 1974). It seems likely that neuroblastoma 
cells develop due to an alteration in neural differentiation, because the majority of 
neuroblastomas continue to express the MYCN proto-oncogene (Matsunaga et al. 1993). 
Furthermore, the more aggressive high risk tumours have MYCN gene amplification (Brodeur 
et al. 1993). 
Another factor that seems to have a role in the dysregulation of neural differentiation 
is the anaplastic lymphoma receptor tyrosine kinase (ALK) (Chen et al. 2008, George et al. 
2008, Janoueix-Lerosey et al. 2008, Mosse et al. 2008). It seems that ALK plays a role in the 
normal development of the central and peripheral nervous system since it localizes primarily 
to spinal motor neurons, the sympathetic ganglia, and the dorsal root ganglia during 
development (Degoutin et al. 2009, Hurley et al. 2006, Iwahara et al. 1997, Morris et al. 1997, 
Vernersson et al. 2006), where it is thought to regulate the balance between proliferation and 
differentiation (Cheng and Ott 2010, Mosse, Wood, and Maris 2009, Palmer et al. 2009). 
MYCN amplification, along with ALK mutations or amplification, could give resistance to 
trophic factor withdrawal signals during neuroblastoma initiation, since MYCN acts as a 
classical transcription factor, promoting migration and the expression of individual genes that 
increase cell proliferation (Stafman and Beierle 2016). One of the factors regulated by MYCN 
is the C-Src proto-oncogene, which encodes a membrane-bound tyrosine specific protein 
kinase. In a previous study of human neuroblastoma by Mellstrom et al. (1987) C-Src 
expression was found to correlate positively with neuronal/neuroendocrine differentiation, 
as measured by neuron-specific enolase expression. In addition, later studies by Bjelfman et 
al. (1990), Hedborg et al. (1995) and Matsunaga et al. (1993, 1998) found that the high 
expression of N2-Src, a neuronal isoform of C-Src, was indicative of a higher degree of 
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differentiation or differentiation potential, making this gene a useful biomarker for prognostic 
evaluation of infant neuroblastoma. 
1.3.  Neuroblastoma therapies 
Since clinical heterogeneity is a hallmark of neuroblastoma, current treatments involve a risk-
based approach based on combinations of clinical and biological prognostic markers (Cohn et 
al. 2009). For patients with low- or intermediate-risk neuroblastoma, who have excellent 
outcomes, surgery alone (De Bernardi et al. 2008) or a reduced treatment of chemotherapy 
and resection of the tumour (Rubie et al. 2011) are curative. However, patients with high-risk 
tumours with MYCN amplification undergo cycles of chemotherapy, plus surgery and 
radiotherapy for residual local and metastatic disease (Matthay et al. 1999, Matthay et al. 
2009). These approaches have resulted in improved outcomes, although survival for high-risk 
patients remains poor, emphasizing the need for more effective treatments (Pinto et al. 
2015). 
One of the therapies used as a maintenance treatment with high-risk neuroblastoma 
patients is 13-cis-retinoic acid (Matthay et al. 2009, Matthay et al. 1999). Endogenous retinoic 
acid signalling regulates proliferation, differentiation, and inflammation, although the exact 
mechanisms of action are still unknown (Bushue and Wan 2010). Retinoic acid (RA) derives 
from vitamin A and is a small lipophilic molecule that binds nuclear RA receptors (RARs) 
(Kleiner-Bossaler and Deluca 1971). The binding of RA to a RAR causes the formation of a 
heterodimer complex between RAR and retinoid X receptor (RXR). The RAR–RXR complex 
modulates transcription by binding to DNA at RA response elements (RAREs) located in 
enhancer regions of RA target genes (Duester 2008, Niederreither and Dolle 2008). 
Endogenous RA has an important role during normal development, since it has been seen to 
contribute to the anteroposterior patterning of the neural plate (Glover, Renaud, and Rijli 
2006), to the development of the spinal cord and somites (Diez del Corral et al. 2003). In 
addition, it makes a fundamental contribution to the development of organs and limbs 
(Cunningham and Duester 2015) and the differentiation of the neural retina at later stages of 
development (Kelley, Turner, and Reh 1994). 
Exogenous RA is used by researchers to study the differentiation of neuroblastoma 
cell lines, such as SH-SY5Y cells (Acosta et al. 2009). Nevertheless, some cell lines like SK-N-LP 
or LA1-55N do not show changes in morphology when treated with this molecule (Acosta et 
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al. 2009). Moreover, exogenous RA is usually only effective against minimal residual disease 
and does not prevent recurrence from larger tumours, thus leading researchers to seek new 
differentiation strategies for refractory tumours.  
A poorly characterised neuronal splice variant of the C-Src protein, N2-Src, was previously 
shown to correlate with neuronal differentiation and neuroblastoma outcome for patients 
(Mellstrom et al. 1987, Bjelfman et al. 1990, Matsunaga et al. 1993, Hedborg et al. 1995, 
Matsunaga et al. 1998), therefore being a potential novel differentiation factor that will be 
investigated in this study. 
1.4.  Src kinase 
The Src family of non-receptor tyrosine kinases (SFKs) plays a fundamental role in multiple 
cellular processes, including proliferation, differentiation, migration and membrane 
trafficking (Roskoski 2015).  
The SFK family shares a conserved structure (Fig. 2), which contains from the N- to C-
terminus (Brown and Cooper 1996, Thomas and Brugge 1997): an N-terminal 14-carbon 
myristoyl group SH4 domain, which facilitates the attachment of Src to membranes and is 
required for Src’s function in cells (Brown and Cooper 1996); a unique domain, exclusive to 
all members of the SFK family; an SH3 domain and an SH2 domain, which participate in 
substrate interaction; an SH1 protein-tyrosine kinase domain (catalytic domain), that provides 
the kinase activity and possesses an autophosphorylation site (Tyr 416) that promotes the 
catalytic activity (Brown and Cooper 1996); a C-terminal regulatory segment, which contains 
a tyrosine residue (Tyr 527) that, if phosphorylated, negatively regulates the kinase activity 
(Brown and Cooper 1996) (Fig. 2). 
Figure 2. Organization of Src. The ~60 kDa Src protein comprises a myristoylated SH4 domain, a unique 
domain, an SH3 domain, an SH2 domain, the catalytic domain (SH1) and a C-terminal tail. 
Regulation of Src activity relies to a large extent on two intramolecular interactions 
(Xu et al. 1999, Roskoski 2015). Firstly, phosphorylation of Tyr 527 in the C-terminal tail 
promotes binding to the SH2 domain, thus favouring an inactive conformation (Fig. 3). 
Secondly, the SH3 domain binds to a proline-rich motif in the linker between the SH2 and the 
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kinase catalytic domain (Fig. 3). Different mechanisms of activation have been reported for 
each member of the SFK family and these include (Moroco et al. 2014): displacement of the 
SH3 domain from the SH2-kinase linker (Briggs and Smithgall 1999), displacement of the C-
terminal tail from the SH2 domain (Brown and Cooper 1996), displacement of both these 
intramolecular interactions (Thomas et al. 1998), and trans-phosphorylation of the activation 
loop tyrosine by a different kinase (Chong et al. 2004). Indeed, displacement of the 
intramolecular regulatory interactions involving the SH2 and the SH3 domains can determine 
kinase activation, promoting a change in the linker conformation and the 
autophosphorylation of the Tyr 416. In particular, it has been shown that C-Src seems more 
susceptible to activation after the SH3 domain displacement (Moroco et al. 2014).  Therefore, 
not only the displacement of the SH2 or SH3 domains by the binding to phosphotyrosine or 
Pro-X-X-Pro motifs respectively in target proteins, but also the dephosphorylation of Tyr 527 
determines the activation of the kinase (Sicheri and Kuriyan 1997, Sicheri, Moarefi, and 
Kuriyan 1997). These events induce disassembly of the intramolecular interactions and, in 
addition, Tyr 416 in the kinase domain is exposed for subsequent autophosphorylation to 
elicit full kinase activity (Fig. 3). 
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Figure 3. Regulation of Src activity. The regulation of Src kinase relies on the phosphorylation of Tyr 
527 in the C-terminal: when this tyrosine is phosphorylated, it binds to the SH2 domain, promoting an 
inactive conformation. Dephosphorylation of Tyr 527 or binding of ligands to the SH2 or SH3 domains 
favour intramolecular interactions which expose Tyr 416 for autophosphorylation that enables full 
kinase activity. 
1.4.1. C-Src kinase 
C-Src is one of eleven members of the SFKs, ubiquitously expressed in vertebrate cells 
(Hoffmann et al. 1983, Parker et al. 1985), and it is involved in the regulation of multiple 
processes, from cell growth, differentiation and cell shape, to migration and survival (Parsons 
and Parsons 2004).  
A homologue of C-Src, v-Src, was first found in 1910 by Peyton Rous while he was 
studying the Rous sarcoma virus (RSV), a chicken retrovirus. V-Src is an activated form of C-
Src kinase that is capable of causing tumours in chickens and transforming cells in culture with 
high efficiency (Rous 1910b, a) and is encoded by the first oncogene to be discovered (Martin 
2001). It was many years later when the cellular form of v-Src kinase, pp60c-src or C-Src, was 
discovered in uninfected cells (Oppermann et al. 1979, Collett et al. 1979). The subsequent 
molecular cloning and sequencing of the chicken C-Src gene and the RSV v-Src gene showed 
that the cellular C-Src oncogene and the RSV v-Src are closely related (Hanafusa 1987, Parker, 
Varmus, and Bishop 1981, Shalloway, Zelenetz, and Cooper 1981, Takeya, Feldman, and 
Hanafusa 1982). However, these genes differ at their C-terminal regulatory segment: 19 
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amino acids of the chicken C-Src are replaced by 12 completely different amino acids in the 
RSV v-Src, thus interfering with its regulation and therefore activity (Takeya and Hanafusa 
1983). Eventually, it was found that there are other viral strains, which contain mutations in 
other domains of the protein (Martin 2004).  
In cells, C-Src is usually maintained in an inactive state through phosphorylation of Tyr 
527 in the C-terminal regulatory domain (Fig. 3), but it can be activated during cellular events 
such as mitosis, or in abnormal events such as by mutation in some human cancers (Bjorge, 
Jakymiw, and Fujita 2000, Ishizawar and Parsons 2004).  
In the nervous system, C-Src kinase is widely expressed and abundant in neuronal 
cells, where it is involved in proliferation and differentiation during development of the 
central nervous system, but it is also highly expressed in fully differentiated neurons, 
suggesting that it regulates additional processes (Parsons and Parsons 2004). Many studies 
show that Src’s function is to upregulate the activity of N-methyl-D-aspartate (NMDA) 
receptors and other ion channels and receptors (Kalia, Gingrich, and Salter 2004), thus 
controlling processes underlying physiological plasticity, such as learning and memory, but 
also in disease, for example in pain and epilepsy (Parsons and Parsons 2004). C-Src is enriched 
in presynaptic nerve terminals, where it has been shown to interact with synapsin I and 
synaptophysin (Onofri et al. 2007). Synapsin I is an abundant synaptic vesicles (SV)-associated 
phosphoprotein, which has a pivotal role in mature neurons in regulating neurotransmitter 
release and short term synaptic plasticity, but also during development where it regulates 
synaptic connectivity (Baldelli et al. 2007, Hilfiker et al. 1999). It has been shown that the 
proline-rich COOH-terminal of synapsin I interacts with the SH3 domain of C-Src (McPherson 
et al. 1994, Onofri et al. 2000), thus stimulating its tyrosine kinase activity, which could be 
physiologically relevant for the neuronal signal transduction pathways mentioned above 
(Onofri et al. 1997, Onofri et al. 2007). Synaptophysin  is the most abundant tyrosine 
phosphorylated protein in the synapse, but its function is still not clear (Evans and Cousin 
2005). Clues have come from experiments demonstrating that C-Src activates TI-VAMP 
exocytosis in vitro by phosphorylating its Longin domain (Burgo et al. 2013). In particular, it 
has been seen that the interaction between C-Src and synaptophysin is increased in vivo 
during learning tasks, where long term potentiation (LTP) was proven to increase tyrosine 
phosphorylation on synaptophysin (Mullany and Lynch 1998, Zhao et al. 2000).  
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C-Src has two splice variants expressed solely in neuronal tissue (Brugge et al. 1985, 
Pyper and Bolen 1989), termed N1- and N2-Src (Fig. 4). The N-Srcs’ additional amino acids are 
inserted in the so-called ‘n-src’ loop of the SH3 domain, changing its interaction interface and 
dramatically affecting its binding specificity (Keenan et al. 2015). N1-Src arises from an 
insertion of the N1 mini-exon (six amino acids), while in N2-Src the N1 and N2 mini exons 
insert a total of seventeen amino acids (Fig. 4).  
Figure 4. Splice variants of Src. Amino acid sequences of C-Src, N1-Src and N2-Src SH3 domains. The 
6 amino acids of N1 microexon are found in N1-Src, while the total 17 amino acids of both N1 and N2 
microexons are found in N2-Src. 
Little is known about the functions of N1-Src, but it has often been linked with neuronal 
differentiation during development: for example, Maness and Aubry (1988) show by 
immunocytochemistry analysis that N1-Src localizes in neurite processes and growth cones 
and Cartwright et al. (1988) describe that high expression of N1-Src is concomitant with 
neurogenesis and neuronal growth during early stages of development. Another study by 
Kotani et al. (2007) related N1-Src function to the acquisition of neuronal morphology in 
Purkinje cells, as its overexpression caused deformities in microtubules and disrupted 
dendrite morphogenesis.  
However, while the N1 neuronal splicing of C-Src is conserved from teleost fish to man, 
the N2-Src splice variant is only found in mammals, suggesting a role for higher brain functions 
(Collett and Steele 1992, Raulf, Robertson, and Schartl 1989, Yang et al. 1989).  
1.4.2. N2-Src kinase 
The inclusion of N1 and N2 mini-exons has significant consequences for the structure and thus 
the function and regulation of this kinase.  
Through an in vitro assay, it was demonstrated that the autophosphorylation of Tyr 
416 is higher in N2-Src than in C-Src (Keenan et al. 2015). This finding was confirmed in cells 
and at the same time it was also shown that the levels of phosphorylated Tyr 527 are much 
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lower for N2-Src, accounting for the increase in the kinase activity (Keenan et al. 2015). The 
increase in the kinase activity was then validated by the analysis of tyrosine phosphorylated 
proteins, which were more abundant in N2-Src overexpressing cells than in C-Src cells (Keenan 
et al. 2015). It has been hypothesized that the higher kinase activity seen in N2-Src could be 
dependent on an open conformation of the kinase, due to the diminished affinity of the SH3 
domain for the SH2-kinase catalytic domain linker (Keenan et al. 2015). 
Another difference that was found in N2-Src is a different affinity for SH3 ligand 
peptides, which determines distinct substrate specificity. It has been seen that C-Src 
phosphorylation of an ideal C-Src (Feng et al. 1995) substrate peptide is enhanced by the 
presence of a C-Src ligand (Feng et al. 1995), but not in the case of N2-Src (Keenan et al. 2015), 
thus meaning that the Pro-X-X-Pro motifs in target proteins could differ to those of C-Src. 
Indeed, a number of different proteins bind C-Src but not N2-Src, which led to the hypothesis 
that N2-Src is not just a constitutively activated form of C-Src, but a kinase with a distinct 
substrate specificity. It seems that the SH4 domain is not altered by the insertion of N1 and 
N2 microexons, therefore N2-Src could bind to membranes via myristoylation as in the case 
of C-Src.  
Several papers show that a transcript high expression of N2-Src positively correlates 
with a favourable outcome for neuroblastoma patients (Mellstrom et al. 1987, Bjelfman et al. 
1990, Matsunaga et al. 1993, Hedborg et al. 1995, Matsunaga et al. 1998). In particular, N2-
Src has been associated with a less metastatic disease and a longer event free survival in 
patients (Matsunaga et al., 2000), link that was further confirmed in 2005 in a study by Terui 
et al. who correlated N2-Src with both a positive outcome. Strong evidences show that N2-
Src may be favourably expressed in neuroblastomas discovered by mass screening, rather 
than by symptom (Matsunaga et al., 2000). These tumours are largely benign, with between 
70 -90% being of favourable, stage I, II or the spontaneously regressing 4S and tend not to be 
Myc amplified (Bessho, 1998).  
In 1993 Matsunaga et al. showed that a pattern of neuronal Src expression is matched 
by an ability to differentiate neuroblastoma cell lines under cAMP/Retinoic Acid. For example, 
they showed that SK-N-SH neuroblastoma cells have C-Src as the dominant isoform while N2-
Src is entirely absent (Matsunaga et al., 1993). This data could suggest that a large number of 
N2-Src expressing neuroblastoma tumours are resolved without any treatment. 
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It has therefore been hypothesized that N2-Src kinase is able to induce differentiation 
in neuroblastoma cells, perhaps due to its higher kinase activity and different substrates in 
comparison to the ubiquitously expressed C-Src kinase. Indeed, preliminary data from the 
theses of previous research students in the Evans laboratory showed that this kinase is able 
to induce the extension of neurite-like processes in neuroblastoma cell lines (SK-N-AS and 
Kelly), even those that are retinoic acid-resistant, confirming the previously speculated role 
of N2-Src in the acquisition of neuronal morphology (Hernández Pérez 2015, Lewis 2014, 
Keenan et al. 2017). These data are the reason why N2-Src kinase was selected as the 
candidate to taken into further examination as a possible neuroblastoma differentiation 
strategy. 
In work by Philip Lewis, HeLa cells stably transfected with N2-Src kinase were treated 
with and without sodium pervanadate, to inhibit endogenous protein tyrosine phosphatases 
(PTPs) and to activate Src family kinases, and were subjected to anti-phosphotyrosine 
immunoprecipitation. The immunoprecipitates (IP) eluates were processed by tandem mass 
spectrometry (MS/MS). The analysis involved quantitation (using emPAI) of peptide 
abundance between phosphotyrosine immunoprecipitations from control, C-Src and N2-Src 
HeLas. Therefore, peptides that were more abundant in the N2-Src sample represented 
proteins that were preferentially IP’d from N2-Src cells compared to C-Src and control. 
Consequently, the proteins that were enriched in the N2-Src IP were subjected to functional 
clustering of GO terms and interaction analysis by STRING.  
This experiment suggested that N2-Src phosphorylates a significant functional cluster of 
protein members of the coat protein complex II (COPII), involved in endoplasmic reticulum 
(ER)-Golgi trafficking of secreted proteins (Lewis, 2014) (Fig.5). 
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Figure 5. Functional clustering and interaction analysis. N2-Src HeLa cells were treated with and 
without sodium pervanadate and subjected to anti-phosphotyrosine immunoprecipitation. The IP 
eluates were processed by MS-MS and proteins that were enriched in the N2-Src IP were subjected to 
functional clustering of GO terms and interaction analysis by STRING (from Lewis 2014). 
1.5. COPII trafficking 
The COPII complex is a multi-subunit protein complex responsible for the formation of 
membrane vesicles at the ER destined for the cis-Golgi compartment (Fig. 6) (Barlowe et al. 
1994). The coat comprises five subunits: the secretion associated, ras-related, GTPase (Sar1), 
the Sec23-Sec24 ‘inner coat’ complex and the Sec13-Sec31 ‘outer coat’ complex (Fig. 6). 
Sar1 in its GTP-bound form binds to ER membranes and recruits the inner coat 
proteins (Nakano and Muramatsu 1989, Barlowe, d'Enfert, and Schekman 1993). Sec24 
interacts with the cytoplasmic domains of cargo proteins (Fig. 6) and is primarily responsible 
for recruiting them for incorporation into vesicles (Miller et al. 2002, Miller et al. 2003, 
Mossessova, Bickford, and Goldberg 2003) but also Sec23 and Sar1 play a minor role in this 
process (Aridor et al. 2001, Giraudo and Maccioni 2003). The membrane-bound Sar1-Sec23-
Sec24 complex recruits the Sec13-Sec31 outer coat (Salama, Yeung, and Schekman 1993, 
Aridor et al. 1998). The interaction between Sec23 and Sar1 results in stimulation of Sar1 
GTPase activity through stabilization of GTP phosphate groups (Bi, Corpina, and Goldberg 
2002) and the binding of Sec31 to Sec23 and Sar1 further enhance its GTPase activity 
(Antonny et al. 2001, Bi, Mancias, and Goldberg 2007). Therefore, full assembly of the coat 
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stimulates Sar1 GTP-hydrolysis activity (Antonny et al. 2001) and this enables the coat to 
depolymerize and be recycled for another round of vesicle biogenesis (Fig .6). 
Although the five COPII coat proteins described above represent the minimal 
machinery required to bud a transport vesicle, there are additional factors that also 
participate, such as Sec16, a large multi-domain protein that associates peripherally with the 
ER membrane and is essential for ER export in vivo (Espenshade et al. 1995, Watson et al. 
2006), and Sec12, a component that aids in the recruitment of Sar1 to the ER membrane 
through a GDP-GTP exchange (Fig.6). 
Figure 6. COPII vesicles formation. COPII coat formation at the ER is initiated by recruitment of Sar1 
to the membrane in the GTP-bound state. Sar1-GTP recruits Sec23/24 heterodimer through 
interaction with Sec23 while Sec24 recruits cargo into pre-budding complexes. Sec13-31 complex is 
recruited to the inner coat layer through interactions with Sec23 and the coat drives membrane 
curvature, facilitating membrane deformation. Vesicle release from the ER is achieved in a manner 
related to Sar1 GTP hydrolysis. Sec12’s aid in the recruitment of Sar1 and Sec16’s scaffolding role are 
shown (adapted from D'Arcangelo, Stahmer, and Miller (2013)). 
The putative interaction between N2-Src and COPII components, suggested by the 
aforementioned mass spectrometry analysis (Lewis 2014) and the fact that high expression 
of N2-Src correlates with a favourable outcome for neuroblastoma patients (Matsunaga et al. 
1998), has led to the hypothesis that there could be an interplay between N2-Src and the 
COPII complex, which could be involved in neuroblastoma cell differentiation. 
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1.5.1. The COPII complex in neuronal 
differentiation 
The importance and the role of the COPII components during neuronal differentiation has 
already been widely demonstrated: Sar1, Sec13, Sec31, Sec23 and Sec24 are transcriptionally 
upregulated to direct dendrite development (Iyer et al. 2013); Sar1 and Sec23 Drosophila 
homologues are necessary for correct dendritic growth and, if Sar1 is silenced, the transport 
of specific markers to the plasma membrane of dendrites is blocked (Ye et al. 2007); GABA 
transporter-1 axonal targeting requires Sec24 (Reiterer et al. 2008). Other studies have more 
broadly linked the secretory pathway to dendrite growth (Horton et al. 2005, Tang 2008, 
2001) and in particular Horton et al. (2005) have shown how the polarization of secretory 
trafficking directs cargo for asymmetric neurite growth and morphogenesis. Moreover, the 
transport of phospho- and sphingolipid is extremely important in neuronal differentiation, as 
the protrusion of dendrites and axons requires a great amount of membrane (Lecuit and Pilot 
2003), and the addition of membrane can be also achieved by exocytosis (Gauthier et al. 2009, 
Prager-Khoutorsky and Spira 2009). The mechanism of exocytosis is also used during the 
formation of axons and dendrites to deliver transmembrane and membrane-associated 
proteins, such as neurotransmitter receptors, adhesion proteins and axonal guidance 
proteins, to the outgrowing protrusions (Arimura and Kaibuchi 2007, Tang 2008, 2001). 
Furthermore, the importance of COPII-dependent trafficking in neuronal 
differentiation can be fully appreciated, in particular, in the case of Sec23A deficiency. The 
Sec23A knockout mouse exhibits mid-embryonic mortality associated with the defective 
development of extraembryonic membranes and the re-opening of the neural tube in the 
midbrain area (Zhu et al. 2015). Furthermore, human Sec23A mutations cause the cranio-
lenticulo-sutural dysplasia syndrome (CLSD), a disorder that is primarily characterized by late-
closing fontanels, facial dysmorphisms, skeletal defects and sutural cataract, which links the 
biology of ER to Golgi trafficking with a clinical dysmorphology (Lang et al. 2006). The neuronal 
symptoms related to CLSD have not been fully explored yet, but Boyadjiev et al. (2011) 
reported a CLSD patient with seizures and neurodevelopmental delay. Moreover, it was 
demonstrated that Sec23A mice knockout show altered proliferation of neuroepithelium (Zhu 
et al. 2015). 
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Sec23A mutations also affect neuronal maturation by leading to an inhibition of 
dendrites and axon development. This data suggests that a dedicated role exists for the early 
secretory pathway in dendrites growth, but also in the axon growth, particularly under 
demanding conditions (Aridor and Fish 2009, Aridor et al. 2004, Ehlers 2007). Indeed, the 
study by Iyer et al. (2013) showed that CrebA can regulate high order dendritic branching 
complexity in Drosophila melanogaster through the COPII secretory pathway regulation. The 
overexpression of CrebA and the subsequent elevated levels of Sec31 or Sec23 may be 
capable of influencing the rate of COPII vesicle formation, which in turn could modulate 
dendrite development (Iyer et al. 2013). Furthermore, in a previous study conducted in Evans’ 
laboratory by Hernández Pérez (2015), it was shown that Sec13 and Sec23A co-
immunoprecipitate with N2-Src. In the same study, Sec23A was observed to be constitutively 
tyrosine phosphorylated in cells and the phosphorylation appeared to increase in the 
presence of N2-Src. No tyrosine phosphorylation of Sec13 in cells was detected under any 
condition. A preliminary experiment in the same study by Hernández Pérez (2015) showed 
that overexpression of Sec23A can inhibit the ability of N2-Src to differentiate SK-N-AS 
neuroblastoma cells. 
Taken together, these data suggest a role for N2-Src in neurite-like process growth via the 
regulation of cytoskeletal and membrane dynamics, in particular through the interaction with 
members of the COPII complex. It was speculated that N2-Src binds Sec13 and phosphorylates 
Sec23A (Hernández Pérez 2015). 
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1.6. Aims 
Based on the published and preliminary data described in this chapter, the central hypothesis 
of this study is that N2-Src regulates COPII transport to alter cell morphology and drive 
differentiation.  
The hypothesis will be tested by addressing the following questions:  
• Does N2-Src regulate COPII dependent secretion?  
• Do N2-Src dependent effects on cell morphology require COPII?  
Stable HeLa cell lines that inducibly express FLAG-tagged C-Src or N2-Src upon the addition 
of doxycycline were chosen as the model system for these experiments. In the absence of 
antibodies to N2-Src, these cells provided a robust system for comparing COPII traffic and cell 
behaviour in the presence and absence of N2-Src.  
The migration and morphology of the cells was assayed by time-lapse microscopy and the 
inducible secretion of a fluorescent growth hormone cargo was used as a readout of COPII 
function. Finally, Sec23A shRNA constructs were developed and validated as tools to dissect 
the regulation of Sec23A by N2-Src in future experiments. 
Addressing how N2-Src regulates COPII trafficking and modifies cell migration and 
morphology in a robust model cell line could then be used to gain further insights into 
neuroblastoma differentiation strategies. 
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2. Materials and methods 
2.1. Materials 
SYBR Safe was purchased from Life Technologies. Laemmli sample buffer was purchased from 
Sigma. Precision All Blue molecular weight markers were from Bio-Rad. Restriction enzymes 
XhoI and BglII were purchased from New English Biolabs (NEB). T4 DNA Ligase was purchased 
from Promega. The QIAquick Gel Extraction kit was purchased from (Qiagen) and the mini- 
and midi-prep kits from Machery-Nagel. Complementary oligonucleotides were from 
Integrated DNA Technologies (IDT). XL-10 Gold ultracompetent E coli were from Stratagene.  
The following antibiotics were used: ampicillin (Melford), kanamycin (Sigma-Aldrich), 
penicillin/streptomycin (Gibco), doxycycline hyclate (Santa Cruz Biotechnology), hygromycin 
B. (Invitrogen). DMEM medium and FBS were purchased from Gibco, trypsin/EDTA from 
Invitrogen. Rapamycin was purchased from CELL guidance systems. 
The following primary antibodies were used: mouse α-actin B antibody (Abcam), 
mouse α-FLAG (M2) (Sigma), mouse α-HA (Thermo Scientific), rabbit α-Sec23a (GeneTex), 
rabbit α-growth hormone (Insight Biotechnology), rabbit α-GFP (a generous gift from Dr. Paul 
Pryor, University of York). Secondary HRP conjugated α-mouse and α-rabbit antibodies were 
purchased from Sigma, Molecular Probes’ secondary ALEXA fluor-conjugated antibodies were 
purchased from Invitrogen. Protein G agarose resin was purchased from GenScript. PVDF 
membrane (Immobilon-P) and the Immobilon chemiluminescent HRP substrate were 
purchased from Millipore and autoradiography film was from Santa Cruz.  
Unless stated, all other reagents were purchased from Sigma-Aldrich. 
2.2. Plasmids 
The shRNA sequences to knock down Sec23A were found on the Broad Institute Portal 
(https://portals.broadinstitute.org/gpp/public/) and in a paper by Korpal et al. (2011) (Table 
1). The correct insertion of the sequences into the plasmid vector was verified by sequencing 
(Genomics Lab, Technology Facility, University of York) with an M13reverse primer.  
  
28 
 
Clone ID shRNA 
name 
Sec23A target sequence Match region 
TRCN0000232510 
(Broad Institute) 
shRNA 1 ACCTAGTTATGCTGGTATATC 
(between nucleotide 285 and 305) 
Coding 
sequence (CDS) 
TRCN0000232509 
(Broad Institute) 
shRNA 2 ACGAGATGGAGTCCGATTTAG 
(between nucleotide 39 and 59) 
CDS 
TRCN0000232513 
(Broad Institute) 
shRNA 3 ATGACGGTTGTAACTACTAAA 
(between nucleotide 688 and 708) 
3’UTR 
KD#1 
(Korpal et al. 2011) 
shRNA 4 GCCTACAGCTTTGGTTGGACTT 
(between nucleotide 478 and 498) 
CDS 
Table 1. Oligo sequences and matching regions. 
The pSUPER.mCherry/neo-shRNAs were created by substituting the EGFP open reading 
frame in the pSUPER vector with mCherry excised from pmCherry-N1 (Clontech). Mammalian 
expression plasmids encoding full length C- or N1-Src tagged at the C-terminus with FLAG or 
mCherry were previously described (Keenan et al. 2015). pC4S1-GFP-FM4-GH was a kind gift 
from Dr. Andrew Peden, University of Sheffield (Gordon et al. 2010). 
2.3. Cell culture 
Cells were maintained at 37 °C in a humidified atmosphere with 5 % CO2, in 25 cm2 or 75 cm2 
Corning flasks with canted neck. Flp-in HeLa were cultured in DMEM (containing pyruvate, 
high glucose and glutamine (Gibco)) with 10% FCS and 1% penicillin/streptomycin (pen/strep).  
Flp-in T-Rex HeLa cells stably expressing FLAG-tagged C- or N2-Src under the control 
of a tetracycline-inducible promoter were generated in the Evans lab by Dr Philip Lewis (Lewis 
2014). Where appropriate, the parent Flp-in T-Rex HeLa line was used as a control. HeLa cells 
were cultured in 10% FCS and 1% pen/strep DMEM supplemented with 50 μg/ml hygromycin 
B to maintain selection of the Src-expressing cells.  
Cells were passaged 2-3 times a week after reaching confluency. Passaging cells involved 
the removal of the culture medium, the washing of the cells with 10 ml of PBS and the addition 
of 1x trypsin/EDTA in PBS for 3 to 5 min. Trypsinization was halted by adding 5 or 10 ml of 
culture medium and cells were then centrifuged at 130 g for 5 min at 20 °C. The pellet was 
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resuspended in 1 ml of culture medium and split into flasks for passaging or quantified in a 
haemocytometer (Hawksley) for plating. 
The cell lines used were checked by frequent DNA staining of live cells and were free of 
Mycoplasma spp. 
2.4. Plasmid amplification and purification 
2.4.1. Bacterial transformation 
All transformations were performed using XL-10 Gold ultracompetent E. coli. 50 μl E. coli were 
transformed with 1-5 μg of plasmid DNA and incubated on ice for 30 min. They were then 
heat-shocked for exactly 45 s at 42 °C and incubated on ice for 2 min before adding 400 μl of 
LB medium (10 g tryptone, 10 g NaCl and 5 g yeast extract per litre) prewarmed to 42°C in a 
waterbath and incubated at 37 °C for 1 h at 200 rpm. 200 μl of cultured bacteria were plated 
on agar plates (10 g tryptone, 10 g NaCl, 5 g yeast extract and 20 g agar per litre) containing 
100 μg/ml ampicillin or 50 μg/ml kanamycin, depending on the antibiotic selection of the 
plasmid, and incubated at 37 °C overnight.  
2.4.2. Plasmid purification 
Single colonies from the overnight bacterial transformation cultures were grown in selective 
LB medium at 37 °C overnight before lysis and plasmid purification using the Quick-Spin mini-
prep kit or Midi-Prep kit as per the manufacturer’s instructions. The identity of the plasmid 
was evaluated by performing a restriction digest followed by an agarose gel, with the uncut 
plasmid as a control, and its concentration was measured using a NanoDrop 
spectrophotometer (Technology Facility, University of York). 
2.5. Transient transfection 
The cells were plated 24 h prior to transfection (for the number of cells and the volumes used 
see Table 2) and the coverslips used for transfections in 24 well plates were sterilised in an 
oven at 180 °C for at least 30 min before use.  
Cells were transfected using polyethylenimine (PEI), following the protocol described 
by Boussif et al. (1995). Briefly, DNA and PEI were diluted in serum free DMEM in different 
tubes (for the quantities see Table 2) and the two solutions were mixed and incubated for 20 
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min at room temperature to allow the formation of lipid-DNA complexes before pipetting 
drop-wise onto the culture medium in each well. After 5 h the medium was replaced with 
fresh medium, which contained 1 μg/ml doxycycline to induce expressions of C-Src or N2-Src 
HeLa. Cells were then fixed or lysed 24 h after transfection or 48 h for shRNA experiments. 
Control cells were transfected with empty plasmids and/or did not receive doxycycline 
treatment. 
 Tissue 
culture  
dish 
Coverslip Cell  
number 
Medium  
volume 
(µl) 
DNA  
quantity 
(µg) 
PEI 
volume 
(µl) 
IC 24 well plate Yes 5 x 104 0.5 1 3 
WB 6 well plate No 1 x 105 2 3 6 
IP 100 mm dish No 5 x 105 12 10 30 
Table 2. Details for transient transfection protocols. Different tissue culture dishes were used for 
immunocytochemistry (IC), western blot (WB) and immunoprecipitation (IP) experiments. The type of 
culture dish that was used, the use of coverslips, the number of cells plated the day before 
transfection, the total volume of culture medium in which the cells were transfected and the quantity 
of DNA and reagent volume used per well/flask are specified for each type of experiment. 
2.6. Immunocytochemistry 
2.6.1. Cell fixation and staining 
Cells were stained by immunocytochemistry after transfection or drug treatment and after 
being plated on 13 mm glass coverslips in a 24 well plate. The cells were washed three times 
in 1 ml PBS and then fixed for 20 min at room temperature in 0.5 ml paraformaldehyde (4% 
paraformaldehyde and 4% sucrose in PBS, pH 7.4).  The cells were then washed three times 
in PBS and permeabilised for 30 min in PBS + 1% BSA + 0.1% Triton X-100. The cells were then 
incubated with α-FLAG (M2) primary antibody in 1% BSA in PBS in a dilution of 1:3000 for 2 h 
at 37 °C in a humidified atmosphere. The cells were then washed three times in 1 ml PBS 
before application of the α-mouse ALEXA 594 secondary antibody in PBS + 1% BSA in a dilution 
of 1:500 for 1 h in the dark at room temperature. The coverslips were finally washed three 
times in 1 ml PBS and once with dH2O and air-dried prior to mounting on microscopy slides 
31 
 
using Mowial (10% Mowial, 25% glycerol in 0.1 M Tris pH 8.5, containing 1 μg/ml DAPI). Cells 
transfected with GFP plasmids alone were mounted on microscope slides immediately after 
fixing. Some coverslips were incubated with the secondary antibody alone, in order to control 
for non-specific staining. 
2.7. Microscopy and image analysis 
2.7.1. Fluorescence imaging 
Images were acquired with the digital camera using a Leica AF600 epifluorescence microscope 
with a 100x objective (Technology Facility, Department of Biology, University of York).  
The quantitative analysis of the number of vesicles was performed using the ImageJ 
Squassh plug-in described in 2.7.2. 
2.7.2. “Squassh” segmentation method 
To analyse the changes in the number of the ER secreted vesicles, the HeLa cells that were 
transfected with the pc4s1-GFP-FM4-GH plasmid were stained and the images were acquired 
with a Leica AF600 fluorescent microscope. To segment and quantify the number of vesicles 
for each condition and at each time point, I employed the Squassh plug-in for Image J and the 
protocol described by Rizk et al. (2014)  
This software exploits a segmentation method that is able to connect the 
segmentation task with the biological reality using information about the imaged objects, the 
process of the picture formation and the background noise in the image (Rizk et al. 2014). 
Moreover, this method of segmentation reduces the chance of bias by combining image de-
noising, deconvolution and segmentation, without separating the de-noising or the 
deconvolution of the images beforehand (Paul, Cardinale, and Sbalzarini 2013). 
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The procedure, described by Rizk et al. (2014), starts with the background subtraction, 
based on a rolling ball algorithm (Sternberg 1983), in order to reduce excess fluorescence. 
The plugin requires to enter a ‘rolling ball window size’, which defines a square with sides of 
a length that would not fit within the objects to be detected. The size chosen allows the plugin 
algorithm to analyse intensity histograms in a window that moves across the picture like a 
‘rolling ball’, in order to recognize the most frequently occurring intensity value as the local 
background estimate. To identify each single fluorescent vesicle spreading from the ER, it was 
chosen a rolling ball size of 10 pixels (Fig. 7).  
Figure 7. Illustration of the procedure’s steps used to analyse the cell vesicles using the ImageJ plugin 
"Squassh": background subtraction. In order to reduce the fluorescence excess, the plugin requires 
to enter the rolling ball window size so that a square with that edge length would not fit in the objects 
to be detected.The next step involved the segmentation parameters: it starts by setting the 
regularization parameter, in order to avoid segmenting noise-induced small intensity peaks 
(the value chosen was 0.05). It then requires a value for the minimum object intensity channel 
(the set value for this analysis was 0.150), in order to increase the sensitivity during the 
segmentation process; the plugin also requires setting the noise model corresponding to the 
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microscope and detector used, which in the case of a wide-field microscope used to obtain 
the pictures is a Gaussian model. Finally, the information about the microscope point spread 
function (PSF) are set and these can be either theoretical (which is provided by the software 
for the wide-field microscope, the one used for this experiment) or a measured one (Fig. 8).  
Figure 8. Illustration of the procedure’s steps used to analyse the cell vesicles using the ImageJ plugin 
"Squassh": segmentation parameters. It directly connects the segmentation process with the 
biological reality, by entering parameters like the microscope PSF, the regularization parameter and 
the threshold, to avoid segmenting noise-induced small intensity peaks and for the minimum object 
intensity to be considered. 
It is also possible to select an output which contains the ‘intermediate steps’ (as shown 
in Fig. 7 and 8), the ‘object intensities’, which displays the objects in their estimated 
fluorescence intensities (Fig. 9B), and the ‘object outlines’, that show an overlay of the original 
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image with the segmented outline (Fig. 9C). It is also possible to select ‘save object and image 
characteristics’ to store the quantifications in .csv files, that were used to obtain the number 
of vesicles per picture (Fig. 9D).  
Figure 9. Illustration of the procedure’s steps used to analyse the cell vesicles using the ImageJ plugin 
"Squassh": visualization and output options. The plugin allows to select how to visualize the result of 
the segmentation, like the .cvs file which contains the resulting object quantifications, or the pictures 
of the object intensities or the object outlines, to visualize the estimated fluorescence intensities of 
the objects or the overlay of the original image with the segmented outlines. 
The number of vesicles per cell for each picture at each time point (circa 20 cells per 
time point and per condition) was then carefully analysed and the median was calculated. 
35 
 
2.7.3. Ptychography 
To address the effects of N2-Src on cell migration and morphology the Phasefocus Virtual 
Lens® technology was used. This is a new technique with a ‘lensless’ imaging method, that has 
the advantage of having no associated lens-related aberrations or limitations. The Phasefocus 
technology was integrated with a conventional microscope for conventional imaging, but also 
for optical and geometric flexibility. 
Flp-in T-Rex HeLa and stable C-Src and N2-Src Flp-In-T-Rex HeLa cells were plated on a 
6 well plate at a confluency of 20% 24 h prior to imaging for the free migration assay, while 
for the wound healing assay stable C-Src and N2-Src Flp-In-T-Rex HeLa cells were plated on a 
6 well at a confluency of 100% always 24 h prior to imaging. Where appropriate, cross-shaped 
wounds were introduced using a yellow pipette tip drawn through the cells in two 
perpendicular lines. Time-lapse imaging was performed by placing the 6 well plate in the 
chamber slide on the VL21 microscope and the microscope and the cells were maintained at 
5 % CO2 and 37°C.  
For the random migration assay, images were acquired by sequentially visiting the 3 
wells with a 10x objective with a time of 7.5 min between imaging the same well. The region 
of interest (ROI) for each well, one ROI per well, was 1.03x1.03 mm. Doxycycline (1 µg/ml) 
was added to all wells to induce the expression of C-Src-FLAG and N2-Src-FLAG and the 
pictures were acquired for 48 h.  Doxycycline was added to the Flp-in Hela well too, in order 
to use it as a control. 
For the wound healing assay, doxycycline was added to the wells 24 h before the cross-
shaped wounds were introduced and images were acquired by sequentially visiting the 4 wells 
with a 10x objective with a time of 11.3 minutes between imaging the same well. The ROI for 
each well, two ROIs per well, was 0.83 x 1.66 mm. C-Src and N2-Src Hela cells without the 
addition of doxycycline were used as a control. 
The data were then segmented using the Cell Analysis Toolbox (CAT) automated cell 
tracking software. The segmentation default ‘recipe’ was adjusted to remove the background 
and allow the software to identify the exact morphology of the cells to track (Godden et al. 
2014, O’Toole and Suman 2014).  In order to get an understanding of the kinetic behaviour of 
each different cell for each cell line, the data were then exported by single cell tracking. 
Indeed, the CAT software is able to track each individual cell over time and identify changes 
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in migration and morphological behaviour: it was therefore possible to individualize each cell 
in the ROI, assigning it with an ID and following the kinetic behaviour and morphology over 
the time course experiment. 
2.7.4. Wound healing assay analysis 
To measure the area migrated in a wound healing assay, the multi-image TIF acquired with a 
10x microscope was analysed in ImageJ. The percentage decrease of the wound area over 48 
h was analysed by outlining the wound on the first image of the time-course using the polygon 
tool, then again outlining it at T24 h and at last on the final image of the time-course and the 
area of the wound between these outlines was measured by ImageJ. The data for these time-
courses was then exported and analysed in Microsoft Excel.  
2.8. Immunoprecipitation 
Cells plated in 10 cm dishes were washed three time with PBS, before the addition of 800 µl 
of RIPA buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS, 140 mM NaCl) containing 0.1% β-mercaptoethanol, 0.1% 
protease inhibitors and 1 mM sodium orthovanadate. Both the buffers and samples were kept 
on ice during the whole process. The cells were scraped from the bottom of the dishes using 
a cell scraper, transferred to an Eppendorf tube and incubated on ice for 10 min at 4 °C to 
remove the insoluble fraction. The lysates were spun at 16,000 g for 10 min at 4 °C to remove 
the insoluble fraction and a Bradford assay was performed to determine the protein 
concentration and to allow equal amounts of proteins to be used for each sample (1 mg/ml). 
100 µl of the lysate was kept as ‘input’ and the 700 µl of lysate left were incubated with 3 µl 
of HA antibody overnight on a rotating wheel at 4 °C. Fifteen µl of protein G beads were then 
added for another hour of incubation at 4 °C on a rotating wheel to recover the immune 
complexes, the beads were then pelleted for 5 min at 4 °C at 720 g and the supernatant was 
collected to assess the IP efficiency. The beads were resuspended in 0.5 ml of PBS and the 
washing and elution steps were performed using 0.45 µm filter spin columns (Spin-X, Costar), 
which were previously washed twice in PBS. The beads were washed three times in 500 µl 
PBS by pulsing for 30 s in a microcentrifuge at 4 °C and, to elute the complex of interest, 30 
µl of 2x Laemmli buffer was added to the filter tubes and incubated for 10 min on a rocking 
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platform at room temperature. The tubes were finally centrifuged for 10 min at 16,000 g and 
the eluate stored at -20°C. 
2.9. SDS-PAGE and Western blotting 
2.9.1. SDS-PAGE 
Samples were either lysed directly into 2x Laemmli loading buffer or diluted in 2x Laemmli 
loading buffer, then boiled at 95 °C for 10 minutes prior to loading. 
Proteins were separated using the sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). The gels were composed of a resolving gel (375 mM Tris-HCl pH 
8.8, 0.1% SDS, 10 % acrylamide/bisacrylamide, 0.05% APS, 0.01% TEMED in dH2O) and a 
stacking gel (125 mM Tris-HCl pH 6.8, 0.1% SDS, 4% acrylamide, 0.05% APS, 0.01% TEMED in 
dH2O). 
The samples were loaded into the gels immersed in 1X SDS running buffer (250 mM 
Tris, 1.92 M glycine, 1 % SDS in dH2O) and run at 190 V until the pre-stained protein molecular 
weight marker (Bio-Rad) reached sufficient resolution of the target protein size. 
2.9.2. Protein transfer 
Proteins were transferred from SDS-PAGE to polyvinylidene difluoride (PVDF) membranes. 
First, the PVDF membrane was activated in 100 % ethanol for at least 1 minute and then 
equilibrated along with the gel in transfer buffer (25 mM Tris, 190 mM glycine, 20 % 
methanol). The gel and the membrane were placed in the cassette between two pieces of 
3MM paper (Millipore) and pads soaked in transfer buffer. 
The assembly was placed in the transfer cell and the transfer was performed at 67 V 
for one hour. At the end of the transfer, the membrane was stained with Ponceau red (0.1% 
Ponceau S, 5% acetic acid in dH2O) to confirm the correct transfer of proteins. 
2.9.3. Western blotting 
All incubations were performed on a rocking platform. The PVDF membrane was washed in 
water and PBS before being blocked for one hour in PBS supplemented with 3% skimmed milk 
at room temperature. The PVDF membrane was then probed with primary antibodies (Table 
3) overnight at 4 °C or for 2 h at room temperature and then the membrane was washed three 
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times for 5 min in PBS Tween (PBS + 0.5% Tween-20). The membrane was incubated for 1 h 
at room temperature with an HRP conjugated secondary antibody diluted in PBS + 0.5% 
Tween and 3% skimmed milk and then it was washed three times for 10 min in PBS + 0.5% 
Tween and incubated for 1 min with chemiluminescent HRP Substrate before visualising 
bands in a darkroom using autoradiography film. Exposure times were variable and ranged 
from 10 s to 20 min, depending on the intensity of the signal.  
To strip a membrane for reprobing with a different antibody, it was incubated three 
times for 10 min at room temperature with stripping buffer (136 mM NaCl, 20 mM glycine, 
pH 2.5) and washed three times in dH2O and then three times in PBS.  
When appropriate, the intensity of the bands was quantified by densitometry using ImageJ. 
Primary Antibody Secondary Antibody 
Antibody Concentration Antibody Concentration 
α -FLAG 1:500 α-mouse IgG HRP 1:5000 
α-Sec23A 1:1000 α-rabbit IgG HRP 1:5000 
α-HA 1:500 α-mouse IgG HRP 1:5000 
α-actin B 1:1000-3000 α-mouse IgG HRP 1:5000 
α-GH 1:700 α-rabbit IgG HRP 1:5000 
α-GFP 1:10000 α-rabbit IgG HRP 1:5000 
Table 3. Western blot antibodies and dilutions. Antibodies used for protein labelling in Western 
blotting experiments and their correspondent secondary antibody. Dilution was made in PBS for 
primary antibodies and in PBS + 3% milk + 0.5% Tween-20 for secondary antibodies. 
2.10. Statistical analysis 
The number of biological replicates was insufficient to perform any statistical analysis, but in 
the experiments in which the n=2 showed a trend that should be confirmed by further 
experiments in order to confirm these interesting preliminary data.   
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3. Results 
3.1. Src kinases expression in inducible cell lines 
To gain better insight into the interaction between COPII traffic and cell behaviour in the 
presence and absence of N2-Src, HeLa cell lines that inducibly express FLAG-tagged C-Src or 
N2-Src upon the addition of doxycycline were chosen as the model system.   
I first verified that the Flp-in HeLa cell lines stably transfected with C-Src or N2-Src 
kinase exhibited doxycycline-dependent expression (Fig. 10A). As shown in Figure 10B and 
10C, in the presence of doxycycline, the expression of C-Src and N2-Src kinases is detectable 
by Western blotting at 6 h, it plateaus at 9-24 h, and it reaches the maximum expression at48 
h. 
Figure 10. Inducible and time dependent expression of Srcs in Flp-in HeLa cell lines. (A) Control, C-
Src or N2-Src expressing HeLa cells were lysed 24 h after the addition of doxycycline (1 µg/ml) and 
separated by SDS PAGE. The gel was immunoblotted for FLAG and actin. (B) C-Src or N2-Src Flp-In HeLa 
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cells were lysed at the indicated times after the addition of doxycycline and the samples were then 
run on a SDS PAGE, prior to immunoblotting with α-FLAG and α-actin. (C) c-Src and N2-Src relative 
protein expression compared to the actin loading control. The expression of the proteins of interest is 
detectable by Western blotting at 6 h, it plateaus at 9-24 h, and it reaches the maximum expression 
at48 h. 
3.2. Src kinases decreases migration in a wound 
healing assay 
As previously demonstrated in a preliminary experiment by Lewis (2014), the inducible 
expression of N2-Src kinase is able to decrease migration and proliferation in a wound-healing 
assay. The wound healing assay is an assay that involves an artificial mechanical scratch on a 
confluent cell monolayer that scrapes off an area covered by cells (Rodriguez, Wu, and Guan 
2005). Cells are then stimulated by the availability of empty space (Poujade et al. 2007) and 
the ones at the edges of the scratch proliferate and move toward the centre of the wound 
area until it is closed (Ascione et al. 2016). To confirm and extend the results obtained by 
Lewis (2014), ptychography was used to gain a better characterisation of cell migration and 
proliferation in a random migration assay. In this study, a Phasefocus ptychography system 
was used (Marrison et al. 2013). Ptychography uses Coherent Diffractive Imaging (CDI) to 
reconstruct a target object from the diffraction pattern it generates when illuminated by a 
source (Maiden and Rodenburg 2009). It can be applied to visible light microscopy to produce 
high resolution quantitative phase images of low-contrast objects, such as unlabelled cells, 
and it works also in transmitted and reflected light applications (Maiden and Rodenburg 
2009). The Phasefocus data can then be used to measure parameters of interest, depending 
upon the specimen and the wavelength used. 
C-Src Hela and N2-Src HeLa cell lines were plated at 100% confluency in a 6 well plate 
in duplicate and 6 h after being plated, doxycycline was added to one C-Src well and one N2-
Src well. The following day a cross-shaped scratch was applied to all of the wells and the cells 
were imaged approximately every 11 min for 48 h with the Phasefocus technology with a 10X 
magnification. There were two rectangular ROIs for each well, measuring 0.83 x 1.66 mm. The 
experiment was repeated twice. 
Representative Phasefocus pictures of the different cell lines at the different time 
points analysed with and without the addition of doxycycline are shown in Fig. 11 and Fig. 12. 
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Figure 11. Representative Phasefocus picture of the C-Src cell line at the different time points 
analysed during the first biological replicate of the wound healing assay, with and without the 
addition of doxycycline to induce the expression of C-Src kinase. 
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As it can be seen from Fig. 11 and Fig. 12 (top pictures), untreated C-Src cells can migrate to 
completely fill the wound area in 48 h, whereas N2-Src cells did not: this may suggest either 
a leaky expression of the N2-Src kinase or fundamental differences in cell behaviour between 
Figure 12. Representative Phasefocus picture of the N2-Src cell line at the different time 
points analysed during the first biological replicate of the wound healing assay, with and 
without the addition of doxycycline to induce the expression of N2-Src kinase. 
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these two cell lines that should be further analysed. As far as it concerns the treated cell lines 
(Fig.11 and Fig 12, bottom pictures), it can be seen that the addition of doxycycline profoundly 
affects the migration of C-Src cells, whereas the effect on the N2-Src ones seems less 
profound. Overall, the N2-Src cells treated with doxycycline, used to induce the expression of 
the kinase in analysis, migrated less into the wound over the 48 h. 
To gain a better understanding on the decrease of the wound area the Phasefocus 
time lapse pictures were analysed with ImageJ software. Fig. 13A shows the quantification of 
the mean change in % wound area. It is possible to see a trend in which the C-Src cells 
receiving the doxycycline treatment were able to decrease the wound area more in both the 
experiments, compared to the N2-Src cells that were treated with doxycycline. Indeed, this 
trend showing the % wound area decrease was greatest at 24-48 h. Interestingly there was a 
high proliferative activity even in the C-Src cell line that did not receive the doxycycline, in 
particularly in the first 24 h after the scratch, compared to the N2-Src cell line that did not 
receive the doxycycline either. However, the difference between the untreated C-Src and N2-
Src cells decreases at the time point 24-48 h, where they have a similarly percentage decrease 
of the wound area (Fig. 13).  
Moreover, by exploiting the Phasefocus technology and the subsequent CAT analysis 
software, it was feasible to analyse the track length of every single cell present in the selected 
ROI. It was observed a trend that the doxycycline treatment increased the median track length 
in C-Src cells. However, when N2-Src expression was elicited by the doxycycline treatment, 
the median track length did not change over the 48 h in which the cell lines were imaged (Fig 
13B).  
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A 
B 
Figure 13. N2-Src expressing cells have reduced cell migration compared to C-Src cells in a wound 
healing assay. C-Src and N2-Src Flp-In HeLa cells cultured in a 6 well plate, in medium containing 
doxycycline or vector to induce the expression of Src kinases, were mounted in the environmental 
chamber (37°C, 5% CO2) of the Phasefocus microscope. Images were acquired every 11.3 min for 48 h 
after the wound, with a ROI size of 0.83 x 1.66 mm. (A) The polygon tool in ImageJ was used to measure 
the area of the wound at 0, 24 and 48 h. The data are plotted as the difference in % coverage of the 
ROI by the wound for the indicated time ranges. (B) The track length of each cell was calculated using 
the CAT segmentation software. Data are plotted as the median of the single cell track length (µm), 
with the error bar showing the standard error of the median. The data are from the analysis of an 
average of 3000 cells per cell line and treatment from two independent experiments. 
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3.3. Src kinases decreases migration in a random 
migration assay 
To expand on the findings in the wound healing assay, it was chosen to analyse the cell 
migrating and proliferative behaviour in a random migration assay. In this assay, cells do not 
have external clues and simply explore their local environment, whereas during the wound-
healing assay the cells at the edge of the wound undertake directed migration until new cell–
cell contacts are established again (Poujade et al. 2007, Liang, Park, and Guan 2007, Jonkman 
et al. 2014). The Flp-in HeLa cell line (used as a control) and the C-Src and N2-Src expressing 
cell lines were plated at a confluency of 20% in a 6 well plate. The following day doxycycline 
was added to the medium and images were acquired every 7.5 min for 48 h with the 
Phasefocus microscope at 10X magnification. The region of interest for each well was 1.03 x 
1.03 mm. 
A representative Phasefocus image of the cell lines at the different time points 
analysed after the addition of doxycycline is shown in Fig.14. 
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Figure 14. Representative Phasefocus picture of the cell lines at the different time points analysed 
during the random migration assay, after the addition of doxycycline to induce the expression of Src 
kinases. 
The tracking data of individual cells obtained were exported from the CAT software and 
the median track length (in µm) was calculated. As shown in Figure 15A, the N2-Src cells show 
a decrease in the median track length after the addition of doxycycline, both after 24 h and 
48 h, compared to the Flp-in HeLa and C-Src HeLa. Surprisingly, the Flp-in control cells had an 
increased track length in the second 24 h following doxycycline treatment. Moreover, Fig. 15B 
shows that the percentage of doxycycline treated N2-Src cells that showed no movement at 
all was almost 18% compared to approximately 11-12% in the other cell lines.  
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Figure 15. N2-Src reduces cell migration in a random migration assay. Control, C-Src and N2-Src Flp-
In HeLa cells cultured in a 6 well plate were mounted in the environmental chamber (37°C, 5% CO2) of 
the Phasefocus microscope and observed for 48 h following the addition of doxycycline. Images were 
acquired every 7.5 min, with a ROI size of 1.03x1.03 mm, and the track length of each cell was 
calculated using the CAT segmentation software. (A) Data are plotted as the median of the single cell 
track length (µm), with the error bar showing the standard error of the median. (B) The number of 
cells that had a track length of zero was divided by the total number of cells analysed by the CAT 
segmentation software to obtain the percentage of cells that did not move over the 48 h of 
observation. The data are from an average of 1500 cells per cell line, from 1 well per condition 
analysed from a single experiment. 
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3.4. N2-Src redistributes and increases the number of 
secretory vesicles 
Neurite or neurite-like process outgrowth, is a mechanism that requires the addition of 
plasma membrane, which is provided by exocytosis of secretory vesicles (Gauthier et al. 2009, 
Prager-Khoutorsky and Spira 2009). I therefore hypothesised that regulation of COPII 
transport by N2-Src might increase the rate of secretion to provide sufficient lipids for the 
membrane dynamics necessary for neuronal differentiation. To observe and measure the 
effect of N2-Src on COPII-dependent secretion, I employed a plasmid encoding a fluorescent 
secretory cargo (kindly provided by Andrew Peden, University of Sheffield) that accumulates 
in the ER and can be induced to secrete by the addition of rapamycin. 
The Peden lab modified the reporter construct included in the Ariad RPD Regulated 
Secretion/Aggregation Kit (Ariad Pharmaceuticals) by adding an N-terminal green fluorescent 
protein (eGFP) tag downstream of the signal sequence, to obtain a pc4s1-GFP-FM4-GH 
plasmid (Fig. 16, from Gordon et al. 2010).  
Figure 16. Schematic of the reporter construct used to measure secretion. SS, signal sequence; eGFP, 
enhanced green fluorescent protein; FM, FKBP mutated; FCS, furin cleavage sequence; hGH, human 
growth hormone; numbers represent amino acids (from Gordon et al. 2010) 
This construct is based on a “reverse dimerization” system (Rollins et al. 2000) in which 
aggregation is the resting state and the ligand breaks up protein-protein interactions. This 
system contains a conditional aggregation domain that self-aggregates, but the constitutive 
aggregation can be blocked by rapamycin, allowing for the signal sequence to drive secretion 
and the FCS to release the soluble GH in response to the ligand. 
The conditional aggregation domain is based around the property of mutant FK506-
binding protein (FKBP) to form ligand-reversible dimers. FKBPs belong to the immunophilin 
family and are involved in several biochemical processes including protein folding, receptor 
signalling, protein trafficking and transcription (Kang et al. 2008). A single mutation (F36M) 
allows the usually monomeric FKBP proteins to become ligand reversible dimers. When 
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mutant FKBPs are linked together, they aggregate so that when expressed in the ER they 
cannot be secreted. If cells are incubated with rapamycin, the ligand that normally induces 
FKBP dimerization, being a reverse dimerization system, the aggregates solubilize and the 
construct is secreted from the cell (Rollins et al. 2000).  
Flp-in, C-Src and N2-Src HeLa were co-transfected with the secretion reporter. On the 
same day, 5 h after the transient transfection, doxycycline was added to the medium to 
induce the expression of C-Src and N2-Src kinases. To verify that the secretion reporter 
construct was expressed by the cell lines and that its expression was equal between the cell 
lines, Flp-in, C-Src and N2-Src HeLa cell lines were transfected with the pc4s1-GFP-FM4-GH 
plasmid, and then treated with 25 µM rapamycin for 0, 60 and 120 min prior to lysis. The 
lysates were compared directly by Western blot for GFP, FLAG and actin (Fig. 17). The 
immunoblot revealed a single band for GFP of 79 kDa, likely representing the GFP-tagged 
cargo without growth hormone. Comparing the loading control (actin) with GFP, there was 
no significant difference in GFP intensity between cell lines or over the time course of 
rapamycin treatment. Moreover, the cell lines that were treated with doxycycline to induce 
the expression of c-Src and N2-Src kinase show a constant expression of the protein of interest 
during the time course. Unfortunately, Fig 17 has too high a background to do densitometry. 
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Indeed, the eGFP tag in the secretion reporter construct permitted secretion to be 
visualized for changes in the vesicle distribution and quantified with optical-based approaches 
(Gordon et al. 2010). This was exploited to analyse changes in the distribution of vesicles 
during the expression of the kinases in analysis. The cell lines, with and without the addition 
of doxycycline to allow the expression of c-Src and N2-Src, were treated with 25 μl of 
rapamycin to induce secretion of the construct. It was observed that in the N2-Src expressing 
HeLa cells, N2-Src kinase induced a redistribution of the vesicles along neurite-like processes, 
which is most apparent 120 min after the addition of rapamycin, which allows the construct 
to be secreted. In contrast, in the other cell lines, the vesicles are located mostly close to the 
nucleus at all the time points analysed (Fig.18). 
  
Figure 17. Expression of the pc4s1-GFP-FM4-GH plasmid in Flp-in HeLa (control), C-Src and N2-Src 
cell lines, with and without the addition of doxycycline. To verify the expression of the pc4s1-GFP-
FM4-GH plasmid between the different cell lines with (B) or without (A) doxycycline, control, C-Src or 
N2-Src HeLa cells were transfected with the plasmid 24 h prior to the addition of 25 μL of rapamycin 
to induce secretion. The cells were then lysed in Laemmli buffer at 0 (control) 60 and 120 min after 
the addition of rapamycin was and analysed by immunoblotting for α-GFP, α-FLAG (Src) and α-actin.  
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Figure 18. Increased number and re-distribution of secretory vesicles along neurite-like processes in 
N2-Src kinase expressing HeLa cells. Flp-in (control), C-Src and N2-Src HeLa cell lines, with and without 
the addition of 1 µg/ml doxycycline were treated with rapamycin (1 µg/ml) and fixed at the indicated 
time points. Fixed cells were stained for Src (Flag; red), GFP (green) and DAPI (blue). Images were 
acquired with a wide-field fluorescent microscope. Scale bar = 50 µm. Insets show vesicles in a 
representative magnified area for each condition at the 120 min (T120) time point. In the N2-Src 
expressing HeLa cells, N2-Src kinase induced a redistribution of the vesicles along neurite-like 
processes, which is most apparent 120 min after the addition of rapamycin. 
To better understand and quantify if N2-Src kinase is not only able to redistribute the 
vesicles along the neurite-like processes, but also to increase the average number of vesicles, 
20 pictures per condition and time point were analysed using the “Squassh” segmentation 
method described in 2.7.2. As can be seen in Fig.19A, the expression of N2-Src causes an 
increase in the mean number of vesicles per cell, which is particularly apparent at 120 min.  
Since the increase in the mean number of vesicles per cell is greatest at 120 min for 
the cells that are expressing N2-Src, the distribution of vesicles per cell at this time point was 
presented with a dot and whisker plot (Fig. 19B). In Fig. 19B, not only the mean, which is a 
measure of central tendency and could be skewed by high values, but also the median 
confirmed the increase in the number of vesicles.  
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Figure 19. N2-Src causes an increase in the volume of COPII transport. The pictures of the different 
HeLa cell lines, with and without doxycycline and after the addition of rapamycin, were analysed 
through the “Squassh” segmentation method (described in 2.7.2). (A) The number of vesicles per cell 
for each condition and at each time point was averaged; the average number of cells analysed for each 
condition is 20, from two independent experiments, and the data are plotted as mean number of 
vesicles per cell. (B) The vesicles distribution at T120 is depicted as a dot and whiskers plot, showing 
the median in black, the mean in red and the full range of the measurements.  
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3.5. Sec23A silencing 
To develop reagents for investigating whether the effect of N2-Src on cell morphology and 
differentiation is mediated via Sec23A I validated four pSUPER constructs designed to silence 
the expression of Sec23A (Fig.20). It was decided to use plasmid-based delivery of short 
hairpin (sh) RNA because we have previously used this system to successfully knockdown 
protein expression in fibroblasts and neurons (Keenan et al., 2017). Furthermore, Korpal et 
al. (2011) were able to knockdown Sec23A using shRNAs to demonstrate it is a functional 
downstream target of miR-200 in metastasis. Complementary oligonucleotides encoding the 
shRNA sequences (see Material and Methods) and sticky ends for BglII and XhoI were 
annealed and ligated into pSUPER.mCherry/neo. The sticky ends were designed such that 
successful ligation would mutate the BglII site and thus clones were screened for a lack of BglII 
cleavage (Fig.20). 
Figure 20. Screening for positive Sec23A-shRNA oligonucleotide ligation into pSUPER by BglII 
digestion. The purified plasmids digested with BglII are in the first four lanes while the last three lanes 
show control examples of an undigested shRNA plasmid, the empty plasmid vector digested with BglII 
and the undigested empty pSUPER plasmid. 
To verify which Sec23A shRNAs were the most effective, two approaches were 
employed: i) attempted knockdown of endogenous Sec23A in HeLa cells and ii) knockdown of 
HA-Sec23A, over-expressed in HeLa cells (Fig.21). Firstly, Flp-in HeLa cells were transfected 
with the shRNAs alone and it was found that shRNAs 3 and 4 were able to decrease the 
endogenous expression of Sec23A (Fig.21A). Secondly, HeLa cells co-transfected with HA-
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tagged Sec23A and the four pSUPER-Sec23A plasmids were assessed for HA 
immunoreactivity. Unfortunately, it was not possible to detect the expression of the HA-
tagged Sec23A protein with an anti-HA antibody (data not shown), possibly due to a lack of 
sensitivity of the HA antibody, since bands were detected with an anti-Sec23A antibody.  
In an attempt to detect the HA-tag of the transfected Sec23A, Flp-in HeLa cells were 
co-transfected with HA-tagged Sec23A and shRNA 3 and the cell lysates were subjected to an 
anti-HA immunoprecipitation. As can be seen in Figure 22B, it was possible to detect the 
presence of HA-Sec23A in the IP samples in both the lanes of HA-Sec23A+empty pSUPER and 
HA-Sec23A+scramble shRNA, while the expression of the protein was silenced in cells co-
transfected with shRNA 3. Unfortunately, it was still not possible to detect the presence of 
the HA-tagged protein in the input, supporting the possibility that the HA antibody is not 
sensitive enough to detect exogenous HA-Sec23A unless enriched by immunoprecipitation. 
When the membrane was reprobed with the antibody against Sec23A, it was possible to 
detect the protein both in the IP and input samples and it was possible to confirm that the 
shRNA 3 is able to decrease the production of the Sec23A protein (Fig.21B). However, blotting 
with α-Sec23A should produce two bands, which represent the endogenous protein and HA-
tagged one. The HA-tagged Sec23A should be heavier than the endogenous form, but it is 
possible the two bands run on top of each other. 
Despite the promising results obtained, the knock down experiment should be 
repeated in order to confirm the silencing of Sec23A by the shRNA 3 and 4. 
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Figure 21. pSUPER-Sec23A shRNA knockdown of endogenous or overexpressed Sec23A in HeLa cells.  
(A) Flp-in HeLa cells were transfected with pSUPER shRNA (1-4) or non-targeting shRNA constructs for 
48 h, then lysed in Laemmli buffer 2X and run on a SDS PAGE prior to immunoblotting with α-Sec23A 
and α-actin. ShRNA 3 and shRNA4 are able to decrease the endogenous expression of Sec23A, 
confirmed by the analysis of the relative intensities shown aside the Western Blot picture. (B) Flp-in 
HeLa cells were co-transfected with HA-Sec23A and pSUPER shRNA 3 or scramble shRNA for 48 h and 
then lysed. The lysates (inputs) were immunoprecipitated with an anti-HA antibody (IP:HA). Input and 
IP samples were separated by SDS PAGE and immunoblotted with α-HA, α-Sec23A or α-actin. 
Unfortunately, it was possible to detect the presence of the tagged HA-Sec23A only in the IP samples, 
possibly due to a loss of the HA-tag in the input samples. However, the presence of Sec23A was 
detected in both the IP and input samples once the membrane was reprobed with the α-Sec23A, 
where it was possible to notice a decrease in the Sec23A expression, as also confirmed by the analysis 
of the relative intensities shown aside the Western Blot picture.  
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4. Discussion 
C-Src has two splice variants expressed solely in neuronal tissue (Brugge et al. 1985, Pyper 
and Bolen 1989), termed N1- and N2-Src. These two isoforms differ between each other only 
by 11 aminoacids: N1-Src arises from an insertion of the N1 mini-exon (six amino acids), while 
in N2-Src the N1 and N2 mini exons insert a total of seventeen amino acids. Although C-Src is 
found in all metazoans, N-Srcs have a more recent origin: N1-Src arises in low vertebrates 
(teleost fish; Raulf et al., 1989) and N2-Src only found in mammals. 
Little is known about the functions of N1-Src, but it has often been linked with neuronal 
differentiation during development (Cartwright et al., 1988; Maness and Aubry, 1988; Kotani 
et al., 2007).  
In contrast, the role of N2-Src tyrosine kinase in the development of the nervous system 
was first proposed through several clinical studies on neuroblastoma (Mellstrom et al. 1987, 
Bjelfman et al. 1990, Matsunaga et al. 1993, Hedborg et al. 1995, Matsunaga et al. 1998). In 
these studies, it was discovered that the high protein expression of N2-Src kinase positively 
correlates with the neuronal differentiation of neuroblastoma cell lines and a favourable 
outcome in neuroblastoma patients. Specifically, the N2 isoform is more common in infantile 
and localized neuroblastomas compared to metastatic disease (Matsunaga et al. 1998). 
Indeed, preliminary data from research performed in the Evans laboratory show that N2-Src 
kinase is able to induce the extension of neurite-like processes in neuroblastoma cell lines 
(SK-N-AS and Kelly), even those that are retinoic acid-resistant (Hernández Pérez 2015, Lewis 
2014, Keenan et al. 2017). Moreover, the overexpression of this kinase, compared to the 
overexpression of C-Src or N1-Src kinase, produced the most significant effects on HeLa cell 
morphology and migration, thus confirming the previously speculated role of N2-Src in the 
acquisition of neuronal morphology (Lewis, 2014). 
In this study, I have further investigated the relationship between N2-Src and the COPII 
complex in inducing the extension of neurite-like processes. By using a model cell line that 
inducibly expresses N2-Src kinase and through the analysis of morphological and migratory 
parameters, I was able to show an N2-Src trend in decreasing migration. I have also shown 
that N2-Src has a trend in influencing the rate of COPII transport. Moreover, the Sec23A 
silencing shRNAs that I have developed could be used to further investigate the molecular 
basis of this trend in relation to neuronal differentiation. 
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4.1. N2-Src reduces the cell track length 
A previous study performed in my laboratory by Lewis (2014), showed that N2-Src is able to 
decrease cell proliferation in a wound healing assay. To gain further insights into migration in 
the N2-Src inducible cell line I used ptychography to quantify individual cell behaviour over 
time in culture.  
Cell migration has an important role in many cellular processes, such as 
embryogenesis, immune surveillance and wound healing (Petrie, Doyle, and Yamada 2009) 
and it is possible to analyse two different types of migration: a random migration that occurs 
when a cell possesses low intrinsic directionality and explores its local environment (Jain, 
Worthylake, and Alahari 2012), and a directed migration, that may derive from external clues, 
such as chemoattractants, growth factors and extracellular matrix (Huttenlocher 2005). Src is 
involved in the modulation of many cellular processes and deregulation or altered expression 
is associated with human cancers (Acosta et al. 2003, Mayer and Krop 2010). In particular a 
role for Src in cell adhesion and motility was already found by Rohrschneider (1980) in 
fibroblasts transformed with the constitutively active v-Src that showed a round morphology 
and detachment from the extracellular matrix. Moreover, Src kinase promotes adhesion, 
migration and invasion through the direct binding of FAK, a tyrosine kinase (Baumgartner et 
al. 2008) 
In this study, it was possible to give a further insight into the results obtained by Lewis 
(2014), despite the fact that the data obtained need more replicates to facilitate the statistical 
analysis : the decrease in the percentage area of the wound is higher for the C-Src Hela cell 
line treated with doxycycline compared to the N2-Src treated cells, particularly at the time 
point 24-48 h (Fig. 13A). It was also possible to analyse the single cell behaviour and evaluate 
the track length of each cell, thus confirming the trend of the C-Src cells expressing the kinase 
that have a higher median track length, which is indicative of a more explorative behaviour 
(Fig. 13B). Interestingly, C-Src cells not treated with doxycycline showed a higher percentage 
decrease of the wound area in the first 24 h analysed, but the same median track length as 
N2-Src Hela cells not treated: this could be seen as an higher mitotic behaviour of the C-Src 
cells that try to fill the scratched area, noticeable also from the examination of the time-lapse 
pictures.  
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Regarding the random migration assay, the analysis of the time lapse images revealed 
that the C-Src HeLa cells explored their environment more, as evidenced by an increase in the 
single cell track length, compared with N2-Src HeLa cells (Fig. 15A). Moreover, a higher 
number of N2-Src cells did not move at all, compared to the C-Src cells (Fig. 15B). A visual 
examination of the time-lapse picture frames showed an interesting trend that needs to be 
confirmed by more biological replicates: the decrease in the number of cells undergoing 
mitosis between C-Src and N2-Src. While the C-Src cells where frequently dividing 
successfully, the N2-Src cells seemed to attempt dividing by rounding up, but then failing and 
starting to protrude neurite-like processes. Unfortunately, the CAT analysis software was 
unable to quantify the mitotic index of the cells, but this feature should be implemented in 
the future, in order to be able to properly detect and quantify cells that round up. 
During cell adhesion and motility, a role for Src was already indicated by 
Rohrschneider (1980), who observed that transformation with the constitutively active v-Src 
causes a round morphology and detachment from the ECM. In the migration context, a 
fundamental role is played by cell surface receptors and components of the extracellular 
matrix: in particular, integrin receptor binding initiates signals that stimulate tyrosine 
phosphorylation of intracellular proteins including members of the Src family and the focal 
adhesion kinase (FAK), providing a link between the extracellular matrix proteins and 
components of the intracellular space (Carey 1991, Gumbiner 1996, Short, Talbott, and 
Juliano 1998, Sieg et al. 2000). Notably, it has been shown that during cell adhesion, members 
of the Src family kinases translocate to focal adhesions and regulate rearrangement of actin 
structures: for example, the overexpression of an inactive form of Src reduces the rate of 
vascular smooth muscle cell spreading on collagen, while the wild-type form of this kinase 
enhances spreading (Ishida et al. 1999). These observations strengthen the idea that Src 
kinase activity is required for cytoskeletal reorganization and signal transduction at the focal 
adhesion during migration, even if the full activation of Src kinase is achieved only through 
the association with FAK, in a sort of synergism that eventually promote cell migration 
(Carragher et al. 2003, Hsia et al. 2003). 
It would be then useful to explore more deeply the role of Src kinase during motility and 
migration. In particular, it would be interesting understanding the exact role and regulation 
of N2-Src during this cellular process by taking advantage of the live cell imaging and these 
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two assays, considering the many interactions that are known to happen between Src and 
other intracellular components. One possibility would be combining the live cell imagining 
with fluorescent shRNA to knockdown the expression of some protein of interest that may be 
related to this process. More specifically, in order to gain better insights on the interplay 
between Src and the COPII transport during migration, one of the first experiments in this 
direction may profit from the shRNA I developed and tested in this study, to knock down the 
expression of Sec23A and verify differences in cell migration and proliferation. 
4.2. N2-Src redistributes and increases the number of 
available secretory vesicles 
I have studied the effect of N2-Src upon COPII transport by observing vesicular structures 
following release of a fluorescent cargo from the ER in the HeLa cell line that inducibly 
expresses N2-Src kinase. In my experiments, I observed the trend of a redistribution of the 
vesicles along the neurite-like processes that the cells expressing N2-Src kinase possess, which 
could be due to the demand for new membrane to extend these formations (Fig. 18). To gain 
a deeper insight into the trend of N2-Src dependent changes in vesicle distribution, the 
number of vesicles for each cell line and at each time point was quantified in two biological 
replicates and it was observed that N2-Src increases the number of vesicles, most noticeable 
2 h after cargo release (Fig. 19), when more than 80% of the cargo in the pc4s1-GFP-FM4-GH 
plasmid has been secreted (Rollins et al. 2000). 
Neuronal differentiation is a process that requires the establishment of polarity in the 
cell, defined by the oriented extension of axons and dendrites (Bauch, Stier, and Schlosshauer 
1998). Neurons can protrude a long extended axon and elaborate dendritic arbours (Horton 
and Ehlers 2003) that can produce a surface area 10,000 times greater than typical cells, 
producing structures hundreds of microns away from the cell body (Horton and Ehlers 2004). 
The outgrowth of processes is therefore a crucial event during the development of the 
nervous system that involves coordinated and widespread regulation of the cytoskeleton and 
the membrane trafficking machinery (Foletti, Prekeris, and Scheller 1999, da Silva and Dotti 
2002), but it also requires a large addition of plasma membrane (Gauthier et al. 2009, Prager-
Khoutorsky and Spira 2009). Indeed, the principal sites of synthesis of lipid, integral 
membrane proteins and growth factors needed to support localized signalling are the 
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organelles of the secretory pathway, in particular the ER and Golgi apparatus (Horton et al. 
2005). Therefore, in order to establish a polarity, the new membrane produced through the 
secretory pathway is added to the apical side of the cells early in polarization during neurite 
growth in development and differentiation (Tang 2008), also through the exocytosis process, 
that is balanced by the internalization of membrane through endocytosis (Ye et al. 2007). 
It has been demonstrated that targeted secretory trafficking controls the growth of 
plasma membrane in several processes in many different cell types, for example in yeast cell 
during budding, or more in general during cell migration (Bergmann, Kupfer, and Singer 1983, 
Etienne-Manneville and Hall 2003, Kupfer, Dennert, and Singer 1983). In this study, the 
increase in the number of vesicles seen in the HeLa cells that were expressing N2-Src kinase 
is possibly due to the neurite-like processes outgrowth, a mechanism that requires the 
addition of plasma membrane, which is also provided by the process of exocytosis. The spatial 
control over the organization of secretory trafficking may provide a general mechanism for 
the formation of elaborate processes like dendrites and axons (Horton et al. 2005), therefore 
it has also been shown in neurons that the secretory pathway has a unique spatial distribution 
(Gardiol, Racca, and Triller 1999, Horton and Ehlers 2003, Pierce, Mayer, and McCarthy 2001): 
the neuronal Golgi is composed of both Golgi stacks in the cell body and discrete Golgi 
outposts in dendrites that can be synapse-associated (Gardiol, Racca, and Triller 1999, Pierce, 
Mayer, and McCarthy 2001); trans Golgi network (TGN) organelles in dendrites localize at 
sites of neuron-neuron contact (Sytnyk et al. 2002).  
It has been also proven that during dendritic outgrowth there is an increase in the 
number of dendritic ER exit sites (ERES), where secretory cargoes bud from the ER directed 
to the Golgi (Aridor et al. 2001). Consequently, the organization of the secretory trafficking 
during neuronal differentiation relies not only on the spatial distribution, but also on the 
increase of the vesicles budding sites. Indeed, in a previous study in the Evans laboratory 
(Hernández Pérez 2015), it was shown that the protein expression of N2-Src causes 
redistribution of ERES, spreading in a larger perinuclear region that is not restricted anymore 
to the ER-Golgi intermediate compartment (ERGIC) region (Fig.22). This ERES redistribution 
could possibly be an explanation of the trend seen in my study, in which N2-Src expressing 
cells show a redistribution of the vesicles along the outgrowing neurite-like processes. 
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Figure 22. N2-Src induces ERES dispersion in the perinuclear region. Co-expressed N2-Src and Sec23A 
did not colocalise, despite being in the same area. Interestingly, N2-Src overexpression caused a 
redistribution of ERES which is no longer restricted to ERGIC-like staining but distributed in a larger 
perinuclear region, which matches with the region to which N2-Src is localised. (A-C) COS7 cells were 
transfected with a HA-Sec23A or a control plasmid and with an N2-Src-Cherry or a control plasmid. 
The scale bar represents 20 μm. (C1) Magnified pictures of the indicated sections in C (modified from 
Hernández Pérez 2015).  
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Therefore, it is possible to hypothesize that this N2-Src trend seen in my study may be 
due to the larger number of ERES available for the vesicles to bud, but also for the wider area 
available for the ERES distribution (Fig.23). However, this interesting trend that emerges in 
my experiments needs to be confirmed by more biological replicates to facilitate the 
statistical analysis of the data. 
 
However, given the fundamental role of the secretory trafficking in many aspects of 
neuronal function, like synapse formation, synaptic plasticity, but in particular neuronal 
differentiation (Bradke and Dotti 2000, Craig, Wyborski, and Banker 1995, Song and Poo 
1999), it will be important for future studies to verify this increase seen in this biological 
model in a RA-resistant neuroblastoma cell line. Furthermore, it has been already seen and 
demonstrated that phosphorylation of the COPII complex components may activate COPII 
and re-direct it to different pathways. An example of this could be the work of Wang et al. 
2015 and Davis et al. 2016, in which they demonstrated how the phosphorylation of Sec24, a 
Figure 23. Possible model for N2-Src induced increase of the number of vesicles in N2-Src expressing 
HeLa cells. Under low N2-Src levels, COPII vesicles are formed at ERES and transported to the ERGIC, 
from where cargoes continue their delivery to other organelles. When there is a high expression of 
N2-Src, ERES are increased and redistributed around endosomal compartments and become 
accessible to N2-Src. N2-Src binds and phosphorylates COPII components, modifying vesicle 
formation. As a consequence, the increase seen in the number of vesicles might be due to the increase 
in the number of ERES available, but also for the wider area available for the ERES distribution 
(modified from Hernández Pérez 2015). 
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component of the COPII inner coat, by the casein kinase 1 (CK1), Hrr25, contributes to 
regulate autophagosome abundance during nutrient deprivation. It will be therefore 
fundamental to delineate exactly which member of the COPII complex is phosphorylated by 
N2-Src and how this phosphorylation determines the increase in the number of vesicles seen 
in this study.  
4.3. Sec23A putative role in N2-Src neuroblastoma 
differentiation 
Another finding in the previous study by Hernández Pérez (2015) was the putative 
involvement of Sec23A, protein member of the COPII complex, in N2-Src induced neurite 
outgrowth through the increase in the percentage of cells with processes and in the number 
of processes per cell in both COS7 and SK-N-AS cells. The data were preliminary and the 
number of SK-N-AS cells that presented neurites was too small for statistical analysis, but 
neurite outgrowth in cells that overexpressed Sec23A in addition to N2-Src was abolished 
when compared to N2-Src only overexpressing cells. If this finding is verified, it would 
strengthen the idea of the involvement of COPII transport in neuronal differentiation, in 
particular through the possible interplay between N2-Src and Sec23A. 
In this study, I designed and validated some shRNA constructs able to silence the 
expression of Sec23A, which can then be used to test the aforementioned hypothesis.  
The validation experiments were performed in HeLa cells and it was relevant to 
evaluate the efficacy of the shRNAs in silencing the endogenous expression of Sec23A (Fig. 
22A). Afterwards, in order to further expand the data obtained with the silencing of the 
endogenous expression, I co-transfected the cells with the shRNA 3 for Sec23A and an HA-
tagged Sec23A plasmid in order to overexpress the protein. Unfortunately, it was possible to 
detect the HA-tag only in the IP samples and not in the input ones (Fig. 22B). This result could 
be explained by a sensitivity issue or the loss of the HA-tag altogether, since, when the 
membrane was reprobed for Sec23A, it was possible to detect Sec23A and also to notice a 
decrease in the protein expression for some shRNAs (Fig. 21B). 
I was not able to perform experiments in NB cells, but these tools I validated could be 
used to silence the expression of Sec23A and determine its role in neuroblastoma 
differentiation, and in general in cancer, since so far the role of this protein has been 
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controversial. For example, work by Szczyrba et al. (2011) demonstrated that the 
overexpression of Sec23A reduces cell growth and proliferation in carcinoma cells, but also a 
work by Korpal et al. (2011) showed that the inhibition of Sec23A prevents the secretion of 
metastasis-suppressive proteins, inhibiting migration but increasing colonization. 
In neuroblastoma differentiation, it has been hypothesized that N2-Src could 
phosphorylate Sec23A, which is partially responsible, together with Sec24, for the selection 
of the cargo proteins to incorporate into secretory vesicles. The N2-Src phosphorylation could 
alter vesicle formation and it could also regulate the cargo specificity through Sec23A. 
Consequently, N2-Src may increase the transport of membrane proteins and lipids to promote 
neurite outgrowth or other processes necessary for neuronal differentiation. 
Therefore, complementary experiments silencing Sec23A should be performed in order to 
discriminate between a positive or negative effect of the protein in neuroblastoma, and more 
specific, in N2-Src induced neuronal differentiation. The development and validation of some 
shRNAs is then very useful to help understanding the molecular mechanisms of the secretory 
pathway regulation in the context of neuroblastoma and, in general, neuronal differentiation, 
which is still largely unknown.               
4.4. New insights for neuroblastoma differentiation 
therapies 
My work on the fundamental effect of N2-Src on COPII transport was undertaken with the 
aim of better understanding neuroblastoma differentiation. So far, the long-term survival for 
high-risk neuroblastoma patients with current treatments is approximately 54% (Maris 2010). 
Unfortunately, patients with aggressively treated, high-risk neuroblastoma may develop late 
recurrences, some more than 5 years after completion of therapy (Mertens et al. 2001, 
Cotterill, Parker, et al. 2001, Cotterill, Pearson, et al. 2001) and the overall EFS and OS for 
stage 4 and 4S disease and MYCN-amplification was only 30% at 2 to 5 years after treatment 
in a European study (Canete et al. 2009).  
Despite the use of isotretinoin (also known as 13-cis-retinoic acid) as a maintenance 
treatment for high-risk neuroblastoma cases has been shown to improve the EFS, only 10 to 
20% of patients benefit from this differentiation therapy (PDQ 2017, Reynolds 2004) and the 
neuroblastoma cells left after initial chemotherapy treatments are highly resistant. For this 
reason, there is the need for more efficient and less toxic differentiation therapies. 
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One of the possible therapeutic strategies which is able to induce differentiation and 
senescence in specific neuroblastoma cell lines (Clark, Daga, and Stoker 2013) involves the 
use of oxovanadium compounds (Clark et al. 2015). These compounds are inhibitors of 
protein tyrosine phosphatases (PTPs) (Huyer et al. 1997), the key positive and negative 
modulators of ALK and MYCN action through AKT phosphotyrosine signalling (Qiao et al. 
2013).  
Another possible promising strategy would be to increase the expression of N2-Src 
kinase in the tumour cells, which unfortunately is not a simple therapeutic approach, even if 
it could induce differentiation. 
A new interesting, and maybe more feasible, therapeutic target would be the silencing of 
the protein Sec23A by using an shRNA: if the silencing of Sec23A, member of the COPII, 
determines an increase in neuronal differentiation both in a model system (like the HeLa cells 
used in this study), but also in RA-resistant neuroblastoma cell lines (like the SK-N-AS cells), 
the construct could be delivered to the remaining tumour cell after the surgery, together with 
the RA in order to induce differentiation. Identification of tumour antigens is a growing field, 
due to the expanding field of immunotherapeutic treatments, and new antigens are found 
very frequently. For example, one of the antigens that could be useful to deliver Sec23A 
shRNA may be PRAME: PRAME (preferentially expressed antigen in melanoma), a cancer-
testis antigen (CTA) that was first discovered in a patient with melanoma (Ikeda et al. 1997), 
but later found to be expressed in a large variety of cancer cells.  A study by (Oberthuer et al. 
2004) found that PRAME is universally expressed by high-risk neuroblastoma tumours, which 
are usually associated with poor outcome, therefore the possibility to use the Sec23A shRNA 
in order to differentiate the left tumour cells may be beneficial to the patients. However, a 
deeper understanding of the role of the COPII complex, and in particular Sec23A, during 
neuroblastoma differentiation could help in finding more efficient therapies to treat 
neuroblastoma patients. 
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Definitions and abbreviations 
ALK 
bHLHZip 
Anaplastic lymphoma receptor tyrosine kinase 
Basic-region/helix-loop-helix/leucine-zipper 
BMP Bone morphogenetic protein 
BSA Bovine serum albumin 
CAT Cell Analysis Toolbox 
CDI Coherent diffractive imaging 
CLSD Cranio–lenticulo–sutural dysplasia 
COPII Coat protein complex II 
CrebA cAMP response element-binding protein 
CTA Cancer-testis antigen 
DAPI 4,6-Diamidino-2-phenylindole 
DMEM Dulbecco's modified Eagle's medium 
DNA Deoxyribonucleic Acid 
EDTA 
EFS 
Ethylenediaminetetraacetic acid 
Event free survival 
EGTA 
ER 
ERES 
ERGIC 
Ethyleneglycoltetraacetic acid 
Endoplasmatic reticulum 
ER exit sites 
ER-Golgi intermediate compartment 
FAK Focal adhesion kinase 
FCS Foetal calf serum 
GO Gene Ontology 
GDP Guanosine 5'-Diphosphate 
GFP Green fluorescent protein 
GH Growth hormone 
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GTP Guanosine-5'-triphosphate 
GTPase Guanosinetriphosphatase 
HRP Horseradish peroxidase 
INSS 
IP 
International Neuroblastoma Staging System 
Immunoprecipitation 
LB Lysogeny broth 
LTP 
MYCN 
Long term potentiation 
V-Myc avian myelocytomatosis viral oncogene neuroblastoma 
derived homolog 
MOPS 3-(N-morpholino)propanesulfonic acid 
MS/MS Tandem mass spectrometry 
NGF Neural growth factor 
NMDA N-Methyl-D-aspartate 
OS Overall survival 
PBS Phosphate-buffered saline 
PEI Polyethylenimine 
Pen/strep Penicillin/streptomycin 
PRAME Preferentially expressed antigen in melanoma 
PSF Point spread function 
PVDF Polyvinylidene difluoride 
RA Retinoic acid 
RAREs RA response elements 
RARs RA receptors 
RXR Retinoid X receptor 
RNA Ribonucleic acid 
ROI Region of interest 
69 
 
RSV Rous sarcoma virus 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SFK Src family kinases 
SH Src homology domain 
shRNA Short hairpin RNA 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins 
SV 
TAE 
Synaptic vesicles 
Tris base, acetic acid and EDTA 
TEMED Tetramethylethylenediamine 
TGN 
Tris 
Trans Golgi network 
Tris(hydroxymethyl)aminomethane 
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